Streptozotocin (STZ) selectively targets and kills pancreatic beta cells so it is widely used as an agent to induce Type 1 Diabetes Mellitus (T1DM). STZ models of T1DM are used for assessing mechanisms, screening treatments, and evaluating therapeutic approaches directed at diabetic complications.
Implantable telemetry provides insights into the onset of this disease at a level not previously available as can be seen in the below plot showing the average and standard error measures across 11 rats. Following dosing, as indicated by the arrow and STZ abbreviation, blood glucose values increase as the beta cells are shocked and stop producing insulin, then blood glucose drops as the beta cells die and release all of their insulin, and then over the next day blood glucose increases due to the fact that significantly less insulin is being produced and the animal then achieves a new hyperglycemic homeostasis.
After induction the use of implantable telemetry will similarly provide enhanced insights into effectiveness of managing diabetes through insulin treatments, comparisons of different drugs, and more.